$RGEN · REPLIGEN CORP
Repligen filed an 8-K disclosing privately negotiated exchange and subscription agreements to issue $1.0 billion aggregate principal amount of 0.25% Convertible Senior Notes due 2031. Approximately $541.4M of the new notes will be exchanged for ~$456.8M of existing 1.00% 2028 Notes, and ~$458.6M will be issued for cash. The company will use ~$120M of net proceeds to repurchase shares at $188.64 and the remainder for working capital, M&A, and general corporate purposes.
- $1.0B aggregate principal of 0.25% Convertible Senior Notes due 2031 issued via private exchange/subscription.
- $541.4M of new notes exchanged for ~$456.8M of existing 1.00% 2028 Notes; $458.6M issued for cash.
- Conversion price set at ~$226.37/share, a ~20% premium over the October 29, 2026 closing price.
- $120M of net proceeds earmarked to repurchase common stock at $188.64/share to facilitate the transaction.
- ~$143.2M of 2028 Notes remain outstanding post-close; CFO cites EPS accretion and M&A flexibility.
Markets closed — no regular-session reaction yet; extended-hours move not captured here. The $1B note issuance and concurrent $120M buyback at $188.64 could offset dilution concerns when trading resumes.
A $1B convertible note transaction that simultaneously refinances near-term debt at a sharply lower coupon, raises fresh capital for M&A, and includes a concurrent buyback — a multi-pronged capital structure overhaul.
Biopharma tools companies are increasingly using convertible notes to lock in low rates while extending duration. Repligen's 0.25% coupon reflects strong credit appetite in the life sciences tools space.
The New Notes are convertible into cash and/or shares at Repligen's election, creating potential future dilution up to the Maximum Number of Underlying Shares. The $120M concurrent share repurchase partially offsets but does not eliminate this overhang.